| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3039 | 2013 |
| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2003 | 2016 |
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized MF Van Delft, AH Wei, KD Mason, CJ Vandenberg, L Chen, PE Czabotar, ... Cancer cell 10 (5), 389-399, 2006 | 1458 | 2006 |
| Programmed anuclear cell death delimits platelet life span KD Mason, MR Carpinelli, JI Fletcher, JE Collinge, AA Hilton, S Ellis, ... Cell 128 (6), 1173-1186, 2007 | 1199 | 2007 |
| SOCS3 negatively regulates IL-6 signaling in vivo BA Croker, DL Krebs, JG Zhang, S Wormald, TA Willson, EG Stanley, ... Nature immunology 4 (6), 540-545, 2003 | 1001 | 2003 |
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models A Kotschy, Z Szlavik, J Murray, J Davidson, AL Maragno, ... Nature 538 (7626), 477-482, 2016 | 990 | 2016 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488, 2012 | 933 | 2012 |
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ... The lancet oncology 17 (6), 768-778, 2016 | 922 | 2016 |
| The genomic landscape of hypodiploid acute lymphoblastic leukemia L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ... Nature genetics 45 (3), 242-252, 2013 | 784 | 2013 |
| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826, 2017 | 730 | 2017 |
| Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl WS Alexander, AW Roberts, NA Nicola, R Li, D Metcalf | 668 | 1996 |
| Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense AW Roberts, C Kim, L Zhen, JB Lowe, R Kapur, B Petryniak, A Spaetti, ... Immunity 10 (2), 183-196, 1999 | 666 | 1999 |
| RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis JA Rickard, JA O’Donnell, JM Evans, N Lalaoui, AR Poh, TW Rogers, ... Cell 157 (5), 1175-1188, 2014 | 587 | 2014 |
| Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin S Kimura, AW Roberts, D Metcalf, WS Alexander Proceedings of the National Academy of Sciences 95 (3), 1195-1200, 1998 | 477 | 1998 |
| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 466 | 2020 |
| G-CSF: a key regulator of neutrophil production, but that's not all! AW Roberts Growth factors 23 (1), 33-41, 2005 | 441 | 2005 |
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation … A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, ... J Clin Oncol 27 (11), 1788-1793, 2009 | 434 | 2009 |
| Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma CS Tam, MA Anderson, C Pott, R Agarwal, S Handunnetti, RJ Hicks, ... New England journal of medicine 378 (13), 1211-1223, 2018 | 412 | 2018 |
| Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3 AW Roberts, L Robb, S Rakar, L Hartley, L Cluse, NA Nicola, D Metcalf, ... Proceedings of the national academy of sciences 98 (16), 9324-9329, 2001 | 394 | 2001 |
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, ... The Lancet Oncology 18 (2), 230-240, 2017 | 378 | 2017 |
